Numerous trials have shown the effectiveness of Tamoxifen and aromatase inhibitors in increasing survival in women with ER + ve breast cancer and treatment with tamoxifen and aromatase inhibitors is now standard practice. Here, CYP19A1 is linked to breast carcinoma.